Nexus (NXU) Q4 2024 earnings summary

Executive summary

• Achieved record results in 2024 with sales up 8.3% to EUR 261.5m and net income up 31% to EUR 31.2m, marking 25 years of uninterrupted growth.

• Strong order intake, major project wins, and successful product launches, especially in AI-driven healthcare software.

• Significant investments in R&D (EUR 50.4m, 19% of sales) and two strategic acquisitions (HD Clinical Ltd. and LAPSOFT).

• TA Associates secured 94.95% of shares; delisting from the stock exchange expected in Q1 2025.

Financial highlights

• Revenue rose to EUR 261.5m (+8.3% YoY); EBITDA increased 14.4% to EUR 57.6m; EBIT up 21.4% to EUR 38.7m.

• Net income grew 31% YoY to EUR 31.2m; EPS increased to EUR 1.79 (+28.8%).

• Cash flow from operating activities surged 69.5% to EUR 51.5m; liquid assets at year-end EUR 114m (+17%).

• EBT margin improved to 15.3% (16.2% excluding acquisitions); EBITDA margin at 22%.

• Dividend of EUR 0.22 per share paid; equity ratio at 64.6%.

Outlook and guidance

• Expects continued organic sales and earnings growth through 2026, supported by strong market demand, government funding, and product positioning.

• High order backlog and further tenders anticipated for 2025; integration of acquired companies and delisting to drive additional growth.

• Risks from hospital budget constraints and implementation resources may limit growth in the short term.